Table 1.
Baseline characteristics of patients in the two treatment groups
| Characteristics | VAS (n = 63) |
ECAB (n = 63) |
P value |
|---|---|---|---|
| Sex (male), n (%) | 36 (57.14) | 39 (61.90) | 0.72 |
| Age (years), mean ± SD | 45.14 ± 11.86 | 44.52 ± 15.10 | 0.80 |
| Height (cm), mean ± SD | 1.65 ± 0.07 | 1.66 ± 0.08 | 0.42 |
| Weight (kg), mean ± SD | 61.64 ± 9.24 | 63.42 ± 10.33 | 0.31 |
| BMI (kg/m2), mean ± SD | 22.72 ± 2.70 | 23.03 ± 2.88 | 0.52 |
| BSA (m2), mean ± SD | 1.675 ± 0.152 | 1.704 ± 0.168 | 0.31 |
| Underlying disease | |||
| Diabetes mellitus, n (%) | 3 (4.76) | 4 (6.35) | 1.00 |
| Hypertension, n (%) | 6 (9.52) | 8 (12.70) | 0.78 |
| Lifestyle, n (%) | |||
| Smoking status, n (%) | 7 (11.11) | 10 (15.87) | 0.60 |
| Alcohol consumption, n (%) | 9 (14.29) | 6 (9.52) | 0.584 |
Abbreviations: SD, standard deviation; BMI, body mass index; BSA, body surface area; VAS, treatment with vonoprazan, amoxicillin, and S. boulardii for 10 days; ECAB, treatment with esomeprazole, clarithromycin, amoxicillin, and bismuth for 14 days